Résumé
La stimulation ovulatoire est toujours conduite par la FSH, hormone essentielle du développement folliculaire, associée ou non à la LH. L’ovulation est ensuite déclenchée par HCG.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Références
Gordon K (2002) New developments in gonadotropin pharmacology. Reprod Biomed Online 5: 259–65
The Practice Committee of the American Society for Reproductive Medicine (2008) Gonadotropin preparations: past, present and future. Fertil Steril (Supl 5) S: 13–20
Fostimon EU MRP Registration, data on file, IBSA Laboratories, Lugano (Suisse)
Ulloa-Aguirre A, TImossi C (1998) Structure-function relationship of follicle-stimulating hormone and its receptor. Hum Reprod Update 4: 260–83
Harris SD, Anobile CJ, Mc Loughlin JD et al. (1996) Internal carbohydrate complexity of the oligosaccharide chains of recombinant human follicle-stimulating hormone (Puregon, Org 32489): a comparison with Metrodin and Metrodin-HP. Hum Reprod 2: 807–11
Olijve W, de Boer W, Mulders JW, Wezenbeek PM (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 2: 371–82
Rombauts L, Talmor A (2012) Corifollitropin alfa for female infertility. Expert Opin Biol Ther 12: 107–12
AFSSAPS (2007) Les médicaments inducteurs de l’ovulation: les gonadotrophines. Argumentaire et Recommandations. Actualisation 2007
Wolfenson C, Groisman J, Coulto AS et al. (2005) Batch-to-batch consistency of human derived gonadotrophin preparations compared with recombinant preparations. Repro Med Online 4: 442–54
Pal L, Jindal S, Witt BR, Santoro N (2009) Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertil Steril 89: 1694–701
Smeenk JMJ, Braat DDM, Kremer JAM et al. (2006) Follicle-stimulating hormone isoforms are not useful as pretreatment predictors of outcome in in vitro fertilization: a pilot study. Fertil Steril 85: 1519–22
Letterie GS, Lee JS, Padmanabhan V (2006) Assessment of ovarian reserve by using the follicle-stimulating hormone isoform distribution pattern to predict the outcome of in vitro fertilization. Fertil Steril 86: 1547–8
Emperaire JC (2009) Savoir changer de gonadotrophine. Gynec Obstet Fertil 37: 291–3
Andersen CY (2004) FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect? Reprod Biomed Online 9: 231–6
Pacchiarotti A, Aragona C, Gaglione R, Selman H (2007) Efficacy of a combined protocol of urinary and recombinant follicle-stimulationg hormone used for ovarian stimulation of patients undergoing ICSI cycles. J Assist Reprod Genet 9, 400–5
Selman H, Paciarotti A, El-Danasouri I (2010) Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: impact on oocyte quality and clinical outcome. Fertil Steril 5: 1782–6
Bellavia M, De Geyter C, Streuli I et al. (2013) Randomized controlled trial comparing highly purified (HP-hCG) and recombinant hCG (rhCG) for triggering ovulation in ART. Gynecol Endocrinol 29: 93–7
Al Inany H, Alboughar MA, Mansour RT, Proctor M (2005) Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception. Human Reprod 20: 2061–73
Papanikolaou Eg Bourgain C Fatemi H et al. (2012) Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study. Reprod Endocrinol 21: 50–55
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag France
About this chapter
Cite this chapter
Emperaire, JC. (2013). Quelle gonadotrophine ?. In: Pratique de la stimulation ovulatoire par les gonadotrophines. Springer, Paris. https://doi.org/10.1007/978-2-8178-0398-2_3
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0398-2_3
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0397-5
Online ISBN: 978-2-8178-0398-2
eBook Packages: MedicineMedicine (R0)